2004Experimental and Clinical Endocrinology & DiabetesRequires access

Pituitary function after traumatic brain injury

G Aimaretti

Open publisher page 0 citations

Abstract

Results of recent and ongoing studies have made it clear that TBI poses substantial risk to pituitary function, perhaps even greater than previously believed. It is essential that patients with TBI be screened both prospectively and retrospectively for isolated and multiple pituitary deficits. Furthermore, it is well known that patients with “classical“ hypopituitarism do benefit from hormonal replacement therapy. Patients with TBI-induced hypopituitarism should initially receive critical replacement therapy such as anti-diuretic hormone (ADH), glucocorticoid and thyroid hormones. Gonadal and rhGH replacement therapy should also be introduced if there are deficiencies demonstrated and reconfirmed in a second step. The signs and symptoms of post-traumatic hypopituitarism may be masked by what has been assumed to be merely the clinical sequelae of a TBI. It has been suggested that patients with hypopituitarism following a TBI may benefit with appropriate hormonal replacement. By increasing awareness among physicians of the risks of TBI-induced endocrinopathy and the need for appropriate endocrinological testing, it may be possible to improve the quality of life and enhance the rehabilitation prospects for these patients. In most instances, these patients are first seen and treated by trauma surgeons and neurosurgeons, and subsequently by rehabilitation physicians; they must be knowledgeable about the risks of hypopituitarism so that they can determine which patients are candidates for screening for hypopituitarism. In addition, endocrinologists and internists must be educated about TBI-induced hypopituitarism and encouraged to actively share their expertise with other physicians. Conclusions: Prospects for rehabilitation of patients with TBI-induced hypopituitarism may be enhanced by appropriate neuroendocrine diagnostic approach leading to proper hormonal replacement therapies. Further exploration of this possibility requires an active collaboration between divisions of endocrinology and rehabilitation doctor at the local level to perform a screening of pituitary function in patients following TBI.

About this research paper

What this paper is about

Results of recent and ongoing studies have made it clear that TBI poses substantial risk to pituitary function, perhaps even greater than previously believed. It is essential that patients with TBI be screened both prospectively and retrospectively for isolated and multiple pituitary deficits. Furthermore, it is well known that patients with “classical“ hypopituitarism do benefit from hormonal replacement therapy. Patients with TBI-induced hypopituitarism should initially receive critical replacement therapy such as anti-diuretic hormone (ADH), glucocorticoid and thyroid hormones. Gonadal and rhGH replacement therapy should also be introduced if there are deficiencies demonstrated and reconfirmed in a second step. The signs and symptoms of post-traumatic hypopituitarism may be masked by what has been assumed to be merely the clinical sequelae of a TBI. It has been suggested that patients with hypopituitarism following a TBI may benefit with appropriate hormonal replacement. By increasing awareness among physicians of the risks of TBI-induced endocrinopathy and the need for appropriate endocrinological testing, it may be possible to improve the quality of life and enhance the rehabilitation prospects for these patients. In most instances, these patients are first seen and treated by trauma surgeons and neurosurgeons, and subsequently by rehabilitation physicians; they must be knowledgeable about the risks of hypopituitarism so that they can determine which patients are candidates for screening for hypopituitarism. In addition, endocrinologists and internists must be educated about TBI-induced hypopituitarism and encouraged to actively share their expertise with other physicians. Conclusions: Prospects for rehabilitation of patients with TBI-induced hypopituitarism may be enhanced by appropriate neuroendocrine diagnostic approach leading to proper hormonal replacement therapies. Further exploration of this possibility requires an active collaboration between divisions of endocrinology and rehabilitation doctor at the local level to perform a screening of pituitary function in patients following TBI.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Results of recent and ongoing studies have made it clear that TBI poses substantial risk to pituitary function, perhaps even greater than previously believed. It is essential that patients with TBI be screened both prospectively and retrospectively for isolated and multiple pituitary deficits. Furthermore, it is well known that patients with “classical“ hypopituitarism do benefit from hormonal replacement therapy. Patients with TBI-induced hypopituitarism should initially receive critical replacement therapy such as anti-diuretic hormone (ADH), glucocorticoid and thyroid hormones. Gonadal and rhGH replacement therapy should also be introduced if there are deficiencies demonstrated and reconfirmed in a second step. The signs and symptoms of post-traumatic hypopituitarism may be masked by what has been assumed to be merely the clinical sequelae of a TBI. It has been suggested that patients with hypopituitarism following a TBI may benefit with appropriate hormonal replacement. By increasing awareness among physicians of the risks of TBI-induced endocrinopathy and the need for appropriate endocrinological testing, it may be possible to improve the quality of life and enhance the rehabilitation prospects for these patients. In most instances, these patients are first seen and treated by trauma surgeons and neurosurgeons, and subsequently by rehabilitation physicians; they must be knowledgeable about the risks of hypopituitarism so that they can determine which patients are candidates for screening for hypopituitarism. In addition, endocrinologists and internists must be educated about TBI-induced hypopituitarism and encouraged to actively share their expertise with other physicians. Conclusions: Prospects for rehabilitation of patients with TBI-induced hypopituitarism may be enhanced by appropriate neuroendocrine diagnostic approach leading to proper hormonal replacement therapies. Further exploration of this possibility requires an active collaboration between divisions of endocrinology and rehabilitation doctor at the local level to perform a screening of pituitary function in patients following TBI.

Key concepts: Hypopituitarism, Traumatic brain injury, Medicine, Rehabilitation, Hormone replacement therapy (female-to-male), Pediatrics, Hormone, Intensive care medicine

Related papers

Back to paper searchBrowse research topicsOriginal source
Pituitary function after traumatic brain injury — Research Paper | ScholarLens